Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - ACRYLIC LENS FOR CATARACT TREATMENT

 FDA okays acrylic lens for cataract patients 

 

 BY OUR PHARMA CORRESPONDENT

12th August 2005:  Advanced Medical Optics, Inc. (AMO) announced that the US Food & Drug Administration (FDA) has approved the Tecnis intraocular lens (IOL) on an acrylic platform.

The Tecnis foldable acrylic IOL offers surgeons and their patients the same unique benefits as the Tecnis silicone IOL. AMO is the only company to market IOLs with a claim approved by the FDA for reduced spherical aberration and improved functional vision.

FDA approval of the acrylic IOL marks an important milestone for AMO because it represents the first approved product that combines the outstanding optical technology from its 2004 acquisition of the Pfizer ophthalmic surgical business, an AMO release said.
Visual performance degrades with age, including a loss of functional vision, which is caused by an increase in the optical aberration of the eye that may result in difficulty seeing in low light conditions. Cataract patients with reduced functional vision may be challenged driving at dusk or at night, experience trouble reading or doing work at close range, or lack confidence navigating stairs or unfamiliar settings. The Tecnis lens reduces spherical aberration and improves functional vision in varying light conditions, which is likely to provide a meaningful safety benefit for older drivers and pedestrians with whom they share the road.

In a simulated night driving study, patients viewing a rural road through the Tecnis lens identified a pedestrian hazard significantly sooner than through a traditional spherical IOL. The Tecnis lens also provided a 45-foot advantage in detection and identification distance. At 55 MPH, this would provide an additional 0.5 seconds to perceive and react to a pedestrian hazard.

The eyes, like other parts of the body, actually fall out of balance with age. The cornea and natural crystalline lens of a young person work together to focus light onto the retina. Over time, the natural lens loses some of its ability to balance the cornea, resulting in vision that is not quite as crisp as it used to be. Typical cataract surgery restores cornea/lens balance to a level equivalent to that of a healthy older person.
The Tecnis lens implant restores the cornea/lens balance to a level more like that of a healthy younger person. While most IOLs are made with a spherical (rounded) surface, the Tecnis lens is an aspheric wavefront-designed optic. This design was developed by collecting actual wavefront measurements from human corneas of a representative sample of the population. Then, a modified prolate intraocular lens surface was created that reduces spherical aberration and works with the cornea in a way that more closely resembles the balance of a natural lens and cornea of a young person. The result is improved functional vision for most people after cataract surgery.

Tecnis foldable intraocular lenses are indicated for primary implantation for the visual correction of aphakia in adults in whom a cataractous lens has been removed by phacoemulsification. The lenses are intended to be placed in the capsular bag. 

AMO plans to release the Tecnis foldable acrylic IOL commercially in the US and Europe in September 2005, the release added.

AMO is a global medical device leader focused on the discovery and delivery of vision technologies. Products in the ophthalmic surgical line include intraocular lenses, laser vision correction systems, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgery. AMO owns or has the rights to such ophthalmic surgical product brands as ReZoom, Phacoflex, Clariflex, Array, Sensar, CeeOn, Tecnis and Verisyse intraocular lenses, STAR S4 IR laser vision correction system, WaveScan Wavefront System, CustomVue procedure, Sovereign and Sovereign Compact phacoemulsification systems with WhiteStar technology, Amadeus and Amadeus II microkeratomes, Healon and Vitrax viscoelastics, and the Baerveldt glaucoma shunt. 

BY OUR PHARMA CORRESPONDENT
Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us